NSF believe that the key to business success is to become less risk averse and more risk smart. In this short and concise document, NSF discuss key issues relating to risk management for pharmaceutical companies such as the fear of taking risks, complacency in the work place, ageing facilities and more.
Get risk ready for 2018
NSF's new pharma journal focuses on risk management, with a detailed article on becoming risk smart and a closer look into ICH Q9, quality risk management
You may also like
Manufacturing
![Why CAPA keeps failing and what strong organisations do differently]()
Why CAPA keeps failing and what strong organisations do differently
Read moreThis white paper examines why CAPA systems often close records without preventing recurrence, tracing breakdowns to investigation quality, risk reasoning, and organisational behaviour rather than procedural gaps. It outlines what differentiates compliant CAPA programmes from those that consistently reduce repeat findings and inspection risk
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more. -
You need to be a subscriber to read this article.
Click here to find out more.
You may also like
Manufacturing
![Why CAPA keeps failing and what strong organisations do differently]()
Why CAPA keeps failing and what strong organisations do differently
This white paper examines why CAPA systems often close records without preventing recurrence, tracing breakdowns to investigation quality, risk reasoning, and organisational behaviour rather than procedural gaps. It outlines what differentiates compliant CAPA programmes from those that consistently reduce repeat findings and inspection risk
